N/A
Completed N=94
Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study
Source: ClinicalTrials.gov NCT04815850 ↗Enrolled (actual)
94
Serious AEs
0.0%
Results posted
Sep 2024
Primary outcomePrimary: Change in COVID-19 IgG Antibody (Relative Light Units) — 2.4 relative light unit (RLU)
Summary
Patients on haemodialysis are at higher risk of getting a severe form of COVID-19 if they become infected. Vaccinations are soon to arrive and offer great hope of controlling the current pandemic. It is likely that patients on haemodialysis will be amongst the first people to be offered vaccination against COVID-19 when they become available. While any vaccines offered to these patients will be safe to receive, the effectiveness of the vaccines at giving immunity to being infected with COVID-19 are not known as they have not been explicitly tested in patients on haemodialysis. This study will involve having 3 blood tests to test for an antibody response following vaccination for COVID-19. The first will be 1 month after the first vaccination dose to look at the initial antibody response and the second and third will be 1 month and 6 months after the second vaccination dose.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in COVID-19 IgG Antibody (Relative Light Units) |
2.4 | — |
Eligibility Criteria
Inclusion Criteria
- End stage kidney disease on haemodialysis
- Able and willing to give informed consent
- Have completed or due to complete vaccination against COVID-19
Exclusion Criteria
- Acute kidney injury requiring temporary haemodialysis
- Unable to give informed consent
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT04815850). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.